ACM
MACK

ADAR1 Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

ADAR1 Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-902,350
Closed -$13.3M – 330
2024
Q1 		$13.3M Buy
902,350
+352,932
+64% +$4.96M 3.02% 11
2023
Q4 		$7.37M Buy
+549,418
New +$6.94M 2.63% 8

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ADAR1 Capital Management's MACK Position: Q2 2024 in Review

ADAR1 Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 902,350 shares — an estimated $13.3M sold.

ADAR1 Capital Management first reported a position in MACK in Q4 2023 and held it in 2 quarters. The position peaked at $13.3M in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • ADAR1 Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 902,350 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $13.3M.
  • ADAR1 Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2023 and held it in 2 quarters.
  • ADAR1 Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $13.3M in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.